Gilla Phd Kaplan Net Worth

The estimated Net Worth of Gilla Phd Kaplan is at least $29.1 Million dollars as of 18 May 2018. Gilla Kaplan owns over 27,750 units of Celgene stock worth over $11,235,427 and over the last 16 years Gilla sold CELG stock worth over $17,818,019.

Gilla Kaplan CELG stock SEC Form 4 insider trading

Gilla has made over 88 trades of the Celgene stock since 2004, according to the Form 4 filled with the SEC. Most recently Gilla exercised 27,750 units of CELG stock worth $832,778 on 18 May 2018.

The largest trade Gilla’s ever made was exercising 123,996 units of Celgene stock on 30 October 2006 worth over $332,309. On average, Gilla trades about 11,009 units every 38 days since 2003. As of 18 May 2018 Gilla still owns at least 104,051 units of Celgene stock.

You can see the complete history of Gilla Kaplan stock trades at the bottom of the page.

What’s Gilla Kaplan’s mailing address?

Gilla’s mailing address filed with the SEC is C/O CELGENE CORPORATION, , WARREN, NJ, 11050.

Insider trading at Celgene

Over the last 16 years, insiders at Celgene have traded over $348,919,594 worth of Celgene stock and bought 171,908 units worth $10,354,899 . The most active insider traders include Sol J Barer, Robert J Hugin, and John W Jackson. On average, Celgene executives and independent directors trade stock every 13 days with the average trade being worth of $5,423,484. The most recent stock trade was executed by Jonathan Biller on 31 October 2019, trading 3,125 units of CELG stock currently worth $336,531.

What does Celgene do?

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

What does Celgene’s logo look like?

Complete history of Gilla Kaplan stock trades at Celgene

Celgene executives and stock owners

Celgene executives and other stock owners filed with the SEC include:

• Mark Alles, Chairman of the Board, Chief Executive Officer
• Peter Kellogg, Executive Vice President and Chief Corporate Strategy Officer
• Rupert Vessey, President – Research and Early Development
• Michael Casey, Lead Independent Director
• James Loughlin, Independent Director
• Ernest Mario, Independent Director
• Julia Haller, Director
• Carrie Cox, Independent Director
• Michael Bonney, Independent Director
• Richard Barker, Independent Director
• Michael Friedman, Independent Director
• John Weiland, Independent Director
• Patricia Hemingway Hall, Independent Director
• Hans Bishop, Director
• Jonathan Biller, Executive Vice President, General Counsel
• Alise Reicin, President – Global Clinical Development
• Terrie Curran, President, Global Inflammation & Immunology Franchise
• David Elkins, Chief Financial Officer, Executive Vice President
• Michael F. Pehl, See remarks
• Gerald Masoudi, Executive Vice President
• Gilla Phd Kaplan, Director
• Scott Andrew Smith, See Remarks
• Robert J Hugin, Chief Financial Officer
• Nadim Ahmed, PRES., HEMATOLOGY AND ONCOLOGY
• Lawrence V Stein, See Remarks
• Rodman L Drake, Chief Operating Officer
• Thomas O Daniel, see remarks
• Hoek Andre Van, Controller and CAO
• Walter L Robb, Director
• Graham Burton, See Remarks
• David W Gryska, Chief Financial Officer
• Aart Brouwer, See Remarks
• Sol J Barer, Chief Operating Officer
• Richard C E Morgan, Director
• Arthur H Jr Hayes, Director
• Thomas M Moriarty, see remarks
• Jacqualyn A Fouse, Chief Financial Officer
• Perry A Karsen, see remarks
• Jack L Bowman, Director
• Frank T Cary, Director
• John W Jackson, Chief Executive Officer